# Serological Assays for the detection and characterization of influenza viruses

Canonical: https://abierto.us/opportunities/75d30125r73211

- Solicitation number: 75D30125R73211
- Notice type: Presolicitation
- Status: Closed. Deadline was December 10, 2024 at 2:00 PM EST
- Department: Department of Health and Human Services
- Agency: Centers for Disease Control and Prevention
- Contracting office: CDC Office of Acquisition Services (75D301)
- NAICS: 325413 In-Vitro Diagnostic Substance Manufacturing
- Product or service code: Q301 Reference Laboratory Testing
- Set-aside: Total small business set-aside
- Place of performance: Atlanta, Georgia
- City: Atlanta. https://abierto.us/cities/atlanta-ga-1304000
- First posted: October 17, 2024
- Last posted: December 3, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/5ee8f41b0d6f41feb74970db36b8f76f/view

## Description

Amendment 2 is being issued to extend due date to 12/10/2024 for interested parties to respond for Phase I. This contract is for one 12-month base period, and four, 12-month option periods for the testing of immunological responses of human samples collected from vaccine effectiveness studies of seasonal and pandemic influenza vaccine, randomized controlled trials of influenza vaccines, and/or outbreak investigations using HAI assay.

The testing of human samples will be done in batches and is dependent upon completion of studies or outbreak investigations. The government will provide the schedules for the delivery of the study samples at contract award, if samples are already collected, or two months prior to the study completion. The government will provide standard operating procedures (SOPs) for assay creation to the contractor.

The government will also provide two proficiency panels per each period of performance, within the contract performance period as well as positive and negative controls to the contractor, to confirm proper assay performance by contractor technicians. Samples will be evaluated using government furnished seasonal influenza viruses and/or antigens. In addition to the core requirement above, the contract also consists of an optional task for the development and validation of a new serology assay comparable to HAI.

The government will provide positive and negative controls to the contractor as well as seasonal influenza viruses and/or antigens to validate assay and compare its sensitivity and specificity against HAI.

## Publications

- October 17, 2024: Presolicitation. Notice 84e018421ede492b8b79bd974764c756. https://sam.gov/workspace/contract/opp/84e018421ede492b8b79bd974764c756/view
- November 21, 2024: Presolicitation, due December 3, 2024 at 2:00 PM EST. Notice 7c6255cd52ff46acb7bb6b6092ef6902. https://sam.gov/workspace/contract/opp/7c6255cd52ff46acb7bb6b6092ef6902/view
- December 3, 2024: Presolicitation, due December 10, 2024 at 2:00 PM EST. Notice 5ee8f41b0d6f41feb74970db36b8f76f. https://sam.gov/workspace/contract/opp/5ee8f41b0d6f41feb74970db36b8f76f/view

## Points of contact

- Jennifer Gartzke, jgartzke@cdc.gov, 4044980020

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75d30125r73211.